Apellis earnings up next: Last report before Biogen takeover?

Apellis is expected to report a Q1 loss of 34 cents per share on $203.6 million of revenue, reversing from a surprise Q4 profit of 47 cents per share on $199.9 million. The stock is trading essentially at Biogen’s $41 cash offer, with 20 analysts at hold and a mean price target of $40.93, limiting near-term upside. Investors will focus on the deal timeline, regulatory clearances, and Syfovre sales trends, which generated $587 million in 2025 revenue, down 4% year over year.

Analysis

APLS is no longer a standalone earnings story; it’s a deal-probability instrument with a residual CVR optionality tail. That shifts the relevant P&L driver from quarterly EPS to whether the asset can preserve enough commercial momentum to keep the earn-out math alive—meaning every incremental point of Syfovre share loss now has a convex impact on the perceived value of the contingent payout, even if the headline cash price is locked. In that setup, the true loser is not Biogen, but any late-stage ophthalmology competitor that has to fund share capture against a shrinking but still dominant incumbent with a near-term liquidity exit.

The second-order risk is that management has little incentive to defend near-term revenue if closing is imminent, which can quietly accelerate customer churn and payer normalization into the next few quarters. If the transaction drags, the stock can briefly trade below fair value on headline noise, but downside is likely capped by arb ownership unless a regulatory or timing issue surfaces; the real asymmetry is in the CVR, where current market pricing likely underestimates how hard it is to compound a $1.5B-$2B annual run-rate while copay support is fading. That makes the next two quarters more important than the quarter itself: near-term revenue softness can materially lower the implied probability of any deferred payout.

For BIIB, the acquired asset is modest on the balance sheet but strategically useful if it can be integrated into a broader neurology/ophthalmology platform; the market is likely underappreciating execution risk around post-close prioritization rather than financing. For GS, WFC, and JPM, the article is a small negative read-through because it reinforces that deal-related advisory fees remain hard to bank on until close, and the broader M&A backdrop still appears fragile enough that announced transactions are not translating into durable underwriting momentum. The contrarian view is that the market may be overfocusing on the cash offer and underpricing the probability that a weak operating print makes the CVR effectively out-of-the-money long before any formal close.

Key Decisions for Investors

• Stay long APLS only as a tight arb position into close; expect low single-digit upside to be exhausted, but use any sub-offer dip as a short-duration entry with a hard stop if closing guidance slips.
• Buy BIIB vs. XBI on a 1-3 month horizon: the acquisition adds strategic optionality with limited balance-sheet strain, while the broader biotech basket remains more exposed to multiple compression if deal activity stays selective.
• Avoid chasing APLS common for CVR exposure; if you want optionality, the better risk/reward is a small, defined-risk position in the CVR outcome via structure rather than paying full equity value for a tail that may never monetize.
• Reduce expectations for GS/WFC/JPM M&A fee upside over the next quarter; if you need expression, prefer a relative short in investment-bank-heavy names versus diversified financials until announced-deal conversion improves.
• If APLS prints a materially weaker commercial trend, consider short-dated downside protection on APLS/arb substitutes immediately after earnings, because the market will reprice CVR odds faster than the stock price moves on the cash deal.